Skip to content
Playza Media

Users Discontinuing Weight-Loss Injections Regain Weight Four Times Faster Compared to Dieters

Image of medical syringe and weighing machine
Weight management involves ongoing approaches.

A recent study indicates that individuals who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who stop traditional diet and exercise programs.

Research printed in a prominent health publication points out that while overweight people can lose substantial amounts of their total mass while on the medication, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation.

"Individuals using these drugs must be informed of the risk of fast rebound weight gain when the therapy ends," cautioned expert Dr. Susan Jebb.

Such speed of regain means a return to original mass in about 18 months.

Weighing Therapies

The research, which examined 37 of trials involving thousands of participants, contrasted the results of these new drugs with conventional dieting.

The team emphasize that individuals who shed pounds through dieting typically see a slower weight regain—around 0.1 kg a month—post-intervention.

Understanding the Rapid Regain

Nutrition scientists believe the mode of action of the injections accounts for the accelerated regain.

GLP-1 drugs copy a natural hormone called GLP-1, which controls appetite.

"Long-term administration of the hormone levels far above than normal may cause the system to generate a reduced amount of its endogenous GLP-1, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.

"Discontinuation of this hormone supplement means appetite is uncontrolled, making excessive eating a significant risk."

An Ongoing Disease?

The NHS suggest the jabs for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.

Many experts say that, due to the significant potential of weight regain, the therapy might need to be life-long.

This opinion is reinforced by drug manufacturers, who note that the findings "underscore the long-term nature of obesity," comparing it to managing conditions like high blood pressure.

User Accounts

Users who have come off the medication explain a powerful return of cravings.

"It was like something flipping and you're instantly extremely hungry," said a patient.

The struggle is exacerbated if users have not developed lasting dietary or behavioural modifications during therapy.

Widespread Interest

Figures suggest that millions of people in the UK have tried these injections in the last 12 months, with interest remaining high.

  • Adoption is more common among women compared to males.
  • The 40s and 50s age group shows the greatest usage rates.
  • A large proportion obtain the medications through private prescriptions rather than public health services.

In conclusion, clinicians stress that while the jabs are potent agents for shedding pounds, they are not a standalone solution and long-term success hinges on integrated behavioural management.

TR
The writer

Teresa Roberts

A digital strategist with over a decade of experience in media innovation and brand storytelling across European markets.

Playza Media

Type to search articles.